2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1727 Circulating tumor DNA enables accurate response assessment and risk stratification in DLBCL patients treated with copanlisib plus R-CHOP: A translational study of the copa-R-CHOP trial

Moritz Renner, Evgenii Shumilov I, MD2, Corinna Kosnopfel, PhD3, Bettina Altmann4, Lisa Toma5, Christian Klingler6, Lavanya Ranganathan7, Sabine Bleul8, Martin Dreyling, MD, PhD9, Gerald Illerhaus, MD10, Gerhard Held11, Susanne Ghandili12, Henriette Huber13, Andreas Viardot, MD, PhD14, Vladan Vucinic, MD15, Justus Duyster16, Marita Ziepert17, Georg Lenz, MD18, Florian Scherer, MD, PhD19
1 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany
2 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
3 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
4 Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany
5 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany
6 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany
7 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany
8 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany
9 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
10 Clinic of Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany
11 Department of Internal Medicine I, Westpfalzklinikum, Kaiserslautern, Germany
12 Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
13 Department of Internal Medicine III, Hospital of Karlsruhe, Karlsruhe, Germany
14 Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
15 Department of Hematology, Cell Therapy Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany
16 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany
17 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
18 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
19 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine University of Freiburg, Freiburg im Breisgau, Germany

Introduction

Circulating tumor DNA (ctDNA) from blood plasma has been established as a noninvasive biomarker for accurate disease monitoring and guiding clinical management in patients with diffuse large B-cell lymphoma (DLBCL) receiving standard first-line immunochemotherapy (Krupka et al., J Clin Oncol, 2025; Wang et al., J Clin Oncol, 2025). Yet, its clinical utility in the context of novel first-line combination strategies remains less well explored. We here investigated the value of ctDNA for noninvasive genotyping and longitudinal risk assessment in DLBCL patients with IPI 2-5 treated with R-CHOP in combination with the pan-class I PI3K inhibitor copanlisib within the prospective, multicenter, open-label, non-randomized phase II COPA-R-CHOP trial of the German Lymphoma Alliance (NCT04263584; results of the trial reported in a separate abstract).

 

Methods

We applied targeted next-generation sequencing (NGS) to a total of 98 plasma samples from 43 DLBCL patients treated within the COPA-R-CHOP trial, using the KAPA HyperCap workflows in combination with the KAPA HyperCap DS NHL panel (383 genes, 341 kb, Roche Diagnostics) and custom bioinformatics analysis pipelines (Mutter et al., J Clin Oncol, 2023). Tumor genotypes were assessed in a tumor-agnostic fashion from baseline plasma samples, and ctDNA was monitored in plasma obtained at standardized time points during treatment (after cycles 2 or 3) and at end of treatment (EOT). Concentrations of ctDNA were quantified as haploid genome equivalents per mL plasma (hGE/mL). The prognostic value of ctDNA was assessed at three landmarks: DLBCL diagnosis (n=43 evaluable patients), during therapy (n=33), and EOT (n=22). The primary endpoint of the COPA-R-CHOP trial was 2-year progression-free survival (PFS), and treatment response was assessed by PET-CT according to the Lugano criteria.

 

Results

At DLBCL diagnosis, we identified somatic mutations in 91% of baseline plasma samples (39/43), with a median of 95 variants per patient (range: 6-430) detected by our tumor-agnostic approach. The most frequently mutated genes were IGHV, BCL6, BCL2, DTX1, BCL7A, and TMSB4X. Noninvasive classification by DLBclass from baseline plasma assigned 18% of tumors to C1, 21% to C2, 21% to C3, 8% to C4, and 33% to C5 subtypes. Baseline ctDNA concentrations were significantly higher in patients with an IPI score of 4/5 (p=0.049) and in those with bone marrow infiltration (p=0.006). Cell of origin (COO) and extranodal involvement did not correlate with diagnostic ctDNA levels. Patients with low baseline ctDNA concentrations (<2.5 log hGE/mL) and those achieving early molecular response (EMR) after 2-3 cycles of COPA-R-CHOP (2-log ctDNA decrease) showed significantly superior PFS (p=0.001 and p=0.048, respectively). The EOT ctDNA status was strongly prognostic for PFS (p=0.0001), with ctDNA negativity being highly predictive of durable treatment response, corresponding to a 2-year PFS of 100% (negative predictive value [NPV]: 100% [16/16]). Conversely, ctDNA remained detectable in 6 patients after completion of treatment, of whom 4 experienced lymphoma relapse (positive predictive value [PPV]: 67%). Of note, the two ctDNA-positive cases without subsequent DLBCL relapse were PET-CT positive at EOT (partial response) and received additional therapies after COPA-R-CHOP, which induced long-term remissions. By comparison, EOT PET-CT was also significantly associated with PFS (p=0.003), but less predictive of clinical outcomes than EOT ctDNA, with an NPV of 89% (24/27) and PPV of 55% (6/11).

 

Conclusion

Our findings support ctDNA as a robust noninvasive biomarker for response assessment and risk stratification across multiple landmarks in DLBCL patients undergoing COPA-R-CHOP treatment. EOT ctDNA provided the highest prognostic accuracy and outperformed PET-CT in predicting clinical outcomes, with ctDNA negativity identifying patients at particularly low risk for lymphoma progression, consistent with previous studies on EOT ctDNA in patients receiving standard first-line immunochemotherapy. These results might extend the established clinical utility of ctDNA to emerging first-line combination strategies incorporating targeted agents.

Moritz Renner: No relevant conflicts of interest to declare.